Themis Medicare Intrinsic Value
THEMISMED Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹250.58 | ₹225.52 - ₹275.64 | +150.0% | Book Value/Share: ₹447.78, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹200.46 | ₹180.41 - ₹220.51 | +100.0% | Revenue/Share: ₹368.89, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹74.22 | ₹66.80 - ₹81.64 | -26.0% | EBITDA: ₹8.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹250.58 | ₹200.46 - ₹300.70 | +150.0% | CF Growth: 5.0%, Discount: 15% |
Want to compare with current market value? Check THEMISMED share price latest .
Valuation Comparison Chart
THEMISMED Intrinsic Value Analysis
What is the intrinsic value of THEMISMED?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Themis Medicare (THEMISMED) is ₹250.58 (median value). With the current market price of ₹100.23, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹74.22 to ₹250.58, indicating ₹74.22 - ₹250.58.
Is THEMISMED undervalued or overvalued?
Based on our multi-method analysis, Themis Medicare (THEMISMED) appears to be trading below calculated value by approximately 150.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.48 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.46 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.56x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Themis Medicare
Additional stock information and data for THEMISMED
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹35 Cr | ₹29 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹22 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹16 Cr | ₹4 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹34 Cr | ₹26 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹57 Cr | ₹49 Cr | Positive Free Cash Flow | 8/10 |